Oral Drug Eases Ulcerative Colitis Symptoms Fast
Adults with ulcerative colitis saw symptom improvement within a week in a subgroup of Phase 3 trial data.
Updated on Nov. 3, 2026 in Diabetes

A subgroup analysis of Phase 3 ABTECT trial data found that obefazimod, an oral once-daily treatment for ulcerative colitis, produced clinically meaningful symptom improvement within one week, with improvement continuing over eight weeks. The data were presented at the ACG Annual Scientific Meeting in Nashville, Tenn., and may be of interest to adults living with the condition who are exploring treatment options.
Why it matters
Ulcerative colitis is a chronic inflammatory bowel disease, and many patients struggle with symptoms that persist despite existing therapies. Early signals that symptom relief can appear within a week, and that benefit appears to hold across patients who had prior advanced therapies, offer a new data point for clinicians weighing treatment sequencing.
This subgroup analysis drew on pooled Phase 3 ABTECT 1 and 2 data, with 319 patients receiving obefazimod 25 mg, 636 receiving 50 mg, and 317 receiving placebo. At eight weeks, clinical remission was 13% on the 25 mg dose and 16% on the 50 mg dose, and both doses outperformed placebo on clinical response, symptomatic remission, endoscopic improvement, and HEMI.
The players
ACG Annual Scientific Meeting
The American College of Gastroenterology's yearly conference, where clinicians and researchers present gastrointestinal and liver disease research.
The details
Obefazimod is an oral agent taken once daily. It is thought to restore immune balance in the gut lining by regulating TH-17 cells and activated macrophages, two immune components involved in intestinal inflammation. In this analysis, symptomatic response and remission rose steadily from the first week in both obefazimod groups compared with placebo, with the response rate plateauing over eight weeks while remission continued to climb.
Timeline
Clinically meaningful symptom improvement was first observed within one week of treatment start.
Clinical remission rates at eight weeks were measured in the pooled ABTECT data.
The findings were presented at the ACG Annual Scientific Meeting on October 30, 2026.
Health Landscape
Ulcerative colitis treatment has moved toward targeted and oral options, with many patients still facing persistent symptoms on current therapies. This analysis adds to a growing body of trial data examining whether newer oral agents can deliver meaningful relief across different treatment histories.
If you live with ulcerative colitis and symptoms have not settled on your current treatment, this research is worth raising with your gastroenterologist as you think about options. The early timing of symptom change in these data may be a useful point to discuss when setting expectations with your care team.
The takeaway
Symptom improvement in these data appeared within one week and continued over eight weeks. If you have ulcerative colitis, discuss with your physician whether newer oral options might fit your situation.
Further reading
Explore more in our Diabetes coverage for context on chronic metabolic and inflammatory conditions.
Source note: This article includes information reported by Healio.


